Anacor Pharmaceuticals IncFind Ratings Reports
ANACOR PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ANACOR PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 6.03 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 42.44% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||17.54||15.26|
|Net Income ($mil)||-16.15||-12.96|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||135.77||175.41|
|Total Assets ($mil)||164.0||214.89|
|Total Debt ($mil)||62.26||60.81|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||-84.0||-76.32|
|Return on Assets||-39.28||-36.73|
|Return on Equity||-144.36||-101.79|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||45.37||43.75|
|Div / share||0.0||0.0|
|Book value / share||0.98||1.77|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2585274.0||944662.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 100.83 indicates a significant premium versus the S&P 500 average of 2.79 and a significant premium versus the industry average of 10.99. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ANACOR PHARMACEUTICALS INC proves to trade at a premium to investment alternatives within the industry.
|ANAC NM||Peers 38.24||ANAC NM||Peers 20.79|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ANAC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ANAC's P/CF is negative making the measure meaningless.
|ANAC NM||Peers 113.48||ANAC NA||Peers 1.01|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ANAC's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ANAC 100.83||Peers 10.99||ANAC 21.51||Peers -18.19|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ANAC is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ANAC is expected to have an earnings growth rate that significantly exceeds its peers.
|ANAC 53.18||Peers 379.00||ANAC 166.18||Peers 42.06|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ANAC is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
ANAC has a sales growth rate that significantly exceeds its peers.